Galena (GALE) soars 17.2% after signing a deal with Teva (TEVA) for the commercialization of its...

|About: Galena Biopharma, Inc. (GALE)|By:, SA News Editor

Galena (GALE) soars 17.2% after signing a deal with Teva (TEVA) for the commercialization of its NeuVax breast cancer treatment in Israel. While financial terms weren't disclosed, Teva will make significant royalty payments to Galena on future sales. Israel will be the location of at least four sites for Phase 3 trials of NeuVax.